Tumour suppressor genes in prostate cancer

Seminars in Cancer Biology

Volumn 8, Issue 1, 1997, Pages 11-19

  MacGrogan, Donal ^a   Bookstein, Robert ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Cell adhesion; Cell cycle; Deletion; Inactivation; Suppressor gene

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; CELL ADHESION MOLECULE; PROTEIN P53; RETINOBLASTOMA PROTEIN; UVOMORULIN;

ALLELE; CANCER GROWTH; CARCINOGENESIS; CELL ADHESION; DOWN REGULATION; GENE; GENE ACTIVATION; GENE LOSS; GENE MUTATION; GENE REPRESSION; HUMAN; MALE; METASTASIS; MOLECULAR CLONING; NONHUMAN; PHENOTYPE; PROSTATE CANCER; REVIEW; TUMOR SUPPRESSOR GENE;

EID: 0031079557     PISSN: 1044579X     EISSN: None     Source Type: Journal    
DOI: 10.1006/scbi.1997.0048     Document Type: Article

References (79)

1. 1. Bishop M (1991) Molecular themes in oncogenesis. Cell 64:235-248
2. 2. Rodriguez E, Sreekantaiah C, Changanti RSK (1994) Genetic changes in epithelial solid neoplasia. Cancer Res 54:3398-3406
3. 3. Fearon ER, Vogelstein B (1990) A genetic model for colorectal tumourigenesis. Cell 61:759-767
4. 4. Kinzler K, Vogelstein B (1996) Lessons from hereditary colorectal cancer. Cell 87:159-170
5. 5. Knudson AG (1971) Mutation and cancer: statistical study of retinoblastoma. Proc Natl Acad Sci USA 68:820-823
6. 6. Comings DE (1973) A general theory of carcinogenesis. Proc Natl Acad Sci USA 70:3324-3328
7. 7. Knudson AG (1993) Antioncogenes and human cancer. Proc Natl Acad Sci USA 90:10914-10921
8. 8. Weinberg RA (1995) The retinoblastoma protein and cell cycle control. Cell 81:323-330
9. 9. Bookstein R, Lee W-H (1996) Molecular genetics of the retinoblastoma suppressor gene (Perucho M, Pimentel E, eds), in Critical Reviews in Oncogenesis pp 211-227. CRC Press, Orlando
10. 10. Bookstein R, Shew J-Y, Chen P-L, et al (1990) Suppression of tumourigenicity of human prostate carcinoma cells by replacing a mutated RB gene. Science 247:712-715
11. 11. Bookstein R, Rio P, Madreperla S, et al (1990) Promoter deletion and loss of retinoblastoma gene expression in human prostate carcinoma. Proc Natl Acad Sci USA 87:7762-7766
12. 12. Kubota Y, Fujinami K, Uemura H, et al (1995) Retinoblastoma gene mutations in primary human prostate cancer. Prostate 27:314-320
13. 13. Carter BS, Ewing CM, Ward WS, et al (1990) Allelic loss of chromosomes 16q and 10q in human prostate cancer. Proc Natl Acad Sci USA 87:8751-8755
14. 14. Cunningham JM, Shan A, Wick MJ, et al (1996) Allelic imbalance and microsatellite instability in prostatic adenocarcinoma. Cancer Res 56:4475-4482
15. 15. Phillips SMA, Barton CM, Lee SJ, et al (1994) Loss of the retinoblastoma susceptibility gene (RB1) is a frequent and early event in prostatic tumourigenesis. Br J Cancer 70:1252-1257
16. 16. Sherr C, Roberts JM (1995) Inhibitors of mammalian G1 cyclin-dependent kinases. Genes Dev 9:1149-1163
17. 17. Kamb A (1995) Cell-cycle regulators and cancer. Trends Genet 11:136-140
18. 18. Cairns P, Polascik TJ, Eby Y, et al (1995) Frequency of homozygous deletion at p16/ CDKN2 in primary human tumours. Nat Genet 11:210-212
19. 19. Merlo A, Herman JG, Mao L, et al (1995) 5′ CpG island methylation is associated with transcriptional silencing of the tumour suppressor p16/ CDKN2/ MTS1 in human cancers. Nature Med 1:686-692
20. INK4 protein is restricted to the subset of lung cancer lines that retains wildtype RB. Oncogene 9:3375-3378
21. 21. Koh J, Enders GH, Dynlacht BD, et al (1995) Tumour-derived p16 alleles encoding proteins defective in cell-cycle inhibition. Nature 375:506-510
22. 22. Herman JG, Merlo A, Mao L, et al (1995) Inactivation of the CDKN2/ p16/ MTS1 gene is frequently associated with aberrant DNA methylation in all common human cancers. Cancer Res 55:4525-4530
23. 23. Chen PL, Chen Y, Bookstein R, et al (1990) Genetic mechanisms of tumor suppression by the human p53 gene. Science 250: 1576-1580
24. 24. Lane DP (1992) p53, guardian of the genome. Nature 358:15-16
25. 25. Greenblatt MS, Bennett WP, Hollstein M, et al (1994) Mutations in the p53 tumour suppressor gene: clues to cancer etiology and molecular pathogenesis. Cancer Res 54:4855-4878
26. 26. Soini X Paakko P, Nuorva K, et al (1992) Comparative analysis of p53 protein immunoreactivity in prostatic, lung and breast carcinomas. Yirchows Archiv A Pathol Anat 421:223-228
27. 27. Visakorpi T, Kallioniemi O-P, Heikkinen A, et al (1992) Small subgroup of aggressive, highly proliferative prostatic carcinomas defined by p53 accumulation. J Natl Cancer Inst 84:883-887
28. 28. Bookstein R, MacGrogan D, Hilsenbeck SG, et al (1993) p53 is mutated in a subset of advanced-stage prostate cancers. Cancer Res 53:3369-3373
29. 29. Navone NM, Troncoso P, Pisters LL, et al (1993) p53 protein accumulation and gene mutation in the progression of human prostate carcinoma. J Natl Cancer Inst 85:1657-1669
30. 30. Aprikian AG, Sarkis AS, Fair WR, et al (1994) Immunohistochemical determination of p53 protein nuclear accumulation in prostatic adenocarcinoma. J Urol 151:1276
31. 31. Kallakury BVS, Figge J, Ross JS, et al (1994) Association of p53 immunoreactivity with high Gleason tumour grade in prostatic adenocarcinoma. Hum Pathol 25:92-97
32. 32. Bookstein R (1994) Tumour suppressor genes in prostatic oncogenesis. J Cell Biochem S19:217-223
33. 33. Mirchandani D, Zheng J, Miller GJ, et al (1995) Heterogeneity in intratumour distribution of p53 mutations in human prostate cancer. Am J Pathol 147:92-101
34. 34. Chi S-G, White RWD, Meyers FJ, et al (1994) p53 in prostate cancer: frequent expressed transition mutations. J Natl Cancer Inst 86:926-933
35. 35. Isaacs WB, Carter BS, Ewing CM (1991) Wild-type p53 suppresses growth of human prostate carcinoma cancer cells containing mutant p53 alleles. Cancer Res 51:4716-4720
36. 36. Takeichi M (1991) Cadherin cell adhesion receptors as a morphogenetic regulator. Science 251:1451-1455
37. 37. Vleminckx KL, Vakaet J, Mareel M, et al (1991) Genetic manipulation of E-cadherin expression by epithelial tumour cells reveals an invasion suppressor role. Cell 66:107-119
38. 38. Birchmeier W, Behrens J (1994) Cadherin expression in carcinomas: role in the formation of cell junctions and the prevention of invasiveness. Biochim Biophys Acta 1198:11-26
39. 39. Oda T, Kanai Y, Oyama T, et al (1994) E-cadherin gene mutations in human gastric carcinoma cell lines. Proc Natl Acad Sci USA 91:1858-1862
40. 40. Yoshiura K, Kanai Y, Ochiai A, et al Silencing of the E-cadherin invasion-suppressor gene by CpG methylation in human carcinomas. Proc Natl Acad Sci USA 92:7416-7419
41. 41. Bussemakers MJ, van Moorselaar RJ, Giroldi LA, et al (1992) Decreased expression of E-cadherin in the progression of rat prostate cancer. Cancer Res 52:2916-2922
42. 42. Umbas R, Schalken JA, Aalders TW, et al (1992) Expression of the cellular adhesion molecule E-cadherin is reduced or absent in high-grade prostate cancer. Cancer Res 52:5104-5109
43. 43. Umbas R, Isaacs WB, Bringuier PP, et al (1994) Decreased E-cadherin expression is associated with poor prognosis in patients with prostate cancer. Cancer Res 54:3929-3933
44. 44. Morton RA, Ewing CW, Nagafuchi A, et al (1993) Reduction of E-cadherin levels and deletion of the α-catenin gene in human prostate cancer cells. Cancer Res 53:3585-3590
45. 45. Ewing CM, Ru N, Morton RA, et al (1995) Chromosome 5 suppresses tumourigenicity of PC3 prostate cancer cells: correlation with re-expression of α-catenin and restoration of E-cadherin function. Cancer Res 55:4813-4817
46. 46. Graff JR, Herman JG, Lapidus RG, et al (1995) E-cadherin expression is silenced by DNA hypermethylation in human breast and prostate carcinomas. Cancer Res 55:5195-5199
47. 47. Neumaier M, Paululat S, Chan A, et al (1993) Biliary glycoprotein, a potential human cell adhesion molecule, is down-regulated in colorectal carcinomas. Proc Natl Acad Sci USA 90:10744-10748
48. 48. Rosenberg M, Nedellec P, Jothy S, et al (1993) The expression of mouse biliary glycoprotein, a carcinoembryonic antigen-related gene, is down-regulated in malignant mouse tissues. Cancer Res 53:4938-4945
49. 49. Hsieh JT, Luo W, Song W, et al (1995) Tumour suppressive role of an androgen-regulated epithelial cell adhesion molecule (C-CAM) in prostate carcinoma cell revealed by sense and antisense approaches. Cancer Res 55:190-197
50. 50. Kleinerman D, Troncoso P, Brooks T, et al (1995) The expression of epithelial cell adhesion molecule (C-CAM) in human prostate development and in prostate carcinoma: implication as a tumour suppressor. Cancer Res 55:1215-1220
51. 51. Cho KR, Fearon ER (1995) DCC: linking tumour suppressor genes and altered cell surface interactions in cancer. Curr Opin Genet Dev 5:72-78
52. 52. Klingelhutz AJ, Hedrick L, Cho KR, et al (1995) The DCC gene suppresses the malignant phenotype of transformed human epithelial cells. Oncogene 10:1581-1586
53. 53. Gao X, Honn K, Grignon D, et al (1993) Frequent loss of expression and loss of heterozygosity of the putative tumour suppressor gene DCC in prostatic carcinomas. Cancer Res 53:2723-2727
54. 54. Keino-Masu K, Masu M, Hinck L, et al (1996) Deleted in colorectal cancer (DCC) encodes a netrin receptor. Cell 87:175-185
55. 55. Dong JT, Lamb PW, Rinker-Schaeffer CW, et al (1995) KAI1, a metastasis suppressor gene for prostate cancer on human chromosome 11p11.2. Science 268:884-886
56. 56. Dong J-T, Suzuki H, Pin SS, et al (1996) Down-regulation of the KAI1 metastasis suppressor gene during the progression of human prostatic cancer infrequently involves gene mutation or allelic loss. Cancer Res 56:4387-4390
57. 57. Zou Z, Anisowicz A, Hendrix MJC, et al (1994) Maspin, a serpin with tumour-suppressing activity in human mammary epithelial cells. Science 263:526-529
58. 58. Sheng S, Carey J, Seftor EA, et al (1996) Maspin acts at the cell membrane to inhibit invasion and motility of mammary and prostatic cancer cells. Proc Natl Acad Sci USA 93:11669-11674
59. 59. Lee W-H, Morton RA, Epstein JI, et al (1994) Cytidine methylation of regulatory sequences near the p-class glutathione S-transferase gene accompanies human prostatic carcinogenesis. Proc Natl Acad Sci USA 91:11733-11737
60. 60. Ponder B (1988) Gene losses in human tumours. Nature 335:400-402
61. 61. Visakorpi T, Kallioniemi AH, Syvanen A-C, et al (1995) Genetic changes in primary and recurrent prostate cancer by comparative genomic hybridization. Cancer Res 55:342-347
62. 62. Cher ML, Bova GS, Moore DH, et al (1996) Genetic alterations in untreated prostate cancer metastases and androgen independent prostate cancer detected by comparative genomic hybridization and allelotyping. Cancer Res 56:3091-3102
63. 63. Eagle LR, Yin X, Brothman AR, et al (1995) Mutation of the MXI1 gene in prostate cancer. Nat Genet 9:249-255
64. 64. Hahn SA, Schutte M, Hoque ATMS, et al (1996) DPC4, a candidate tumour suppressor gene at human chromosome 18q21.1. Science 271:350-353
65. 65. Vogelstein B, Fearon ER, Kern SE, et al (1989) Allelotype of colorectal carcinomas. Science 244:207-211
66. 66. Kerangueven F, Essioux L, Dib A, et al (1995) Loss of heterozygosity and linkage analysis in breast carcinoma: indication for a putative third susceptibility gene on the short arm of chromosome 8. Oncogene 10:1023-1026
67. 67. Emmert-Buck MR, Vocke CD, Pozzatti RO, et al (1995) Allelic loss on chromosome 8p12-21 in microdissected prostatic intraepithelial neoplasia. Cancer Res 55:2959-2962
68. 68. Bova GS, Carter BS, Bussemakers MJG, et al (1993) Homozygous deletion and frequent allelic loss of chromosome 8p22 loci in human prostate cancer. Cancer Res 53:3869-3873
69. 69. Fujiwara Y, Ohata H, Emi M, et al (1994) A 3-Mb physical map of the chromosome region 8p21.3-p22, including a 600-kb region commonly deleted in human hepatocellular carcinoma, colorectal cancer, and non-small cell lung cancer. Genes Chromosom Cancer 10:7-14
70. 70. Vocke CD, Pozzatti RO, Bostwick DG, et al (1996) Analysis of 99 microdissected prostate carcinomas reveals a high frequency of allelic loss on chromosome 8p12-21. Cancer Res 56:2411-2416
71. 71. Bookstein R, Levy A, MacGrogan D, et al (1994) Yeast artificial chromosome and radiation hybrid map of loci in chromosome band 8p22, a common region of allelic loss in multiple human cancers. Genomics 24:317-323
72. 72. Bova GS, MacGrogan D, Levy A, et al (1996) Physical mapping of chromosome 8p22 markers and their homozygous deletion in a metastatic prostate cancer. Genomics 35:46-54
73. 73. MacGrogan D, Levy A, Bova GS, et al (1996) Structure and methylation-associated silencing of a gene within a homozygously deleted region of human chromosome band 8p22. Genomics 35:55-65
74. 74. Issa J-PJ, Ottaviano YL, Celano P, et al (1994) Methylation of the oestrogen receptor CpG island links ageing and neoplasia in human colon. Nature Genet 7:536-540
75. 75. Ichikawa T, Nihei N, Suzuki H, et al (1994) Suppression of metastasis of rat prostatic cancer by introducing human chromosome 8. Cancer Res 54:2299-2302
76. 76. Rinker-Schaeffer CW, Hawkins AL, Ru N, et al (1994) Differential suppression of mammary and prostate cancer metastasis by human chromosomes 17 and 11. Cancer Res 54:6249-6256
77. 77. Murakami YS, Brothman AR, Leach RJ, et al (1995) Suppression of malignant phenotype in a human prostate cancer cell line by fragments of normal chromosomal region 17q. Cancer Res 55:3389-3394
78. 78. Sanchez Y Lovell M, Marin MC, et al (1996) Tumour suppression and apoptosis of human prostate carcinoma mediated by a genetic locus within human chromosome 10pter-q11. Proc Natl Acad Sci USA 93:2551-2556
79. 79. Smith JR, Freije D, Carpten JD, et al (1996) Major susceptibility locus for prostate cancer on chromosome 1 suggested by a genome-wide search. Science 274:1371-1374